Epilepsy, which afflicts approximately 4.7 million people in the major markets according to Clarivate epidemiology, is a heterogeneous condition requiring individualized treatment based largely on…
Epilepsy is a heterogeneous condition requiring individualized treatment, especially for patients who are persistently refractory to treatment. Neurologists consider many factors when selecting…
Epi Data Slicer
Epilepsy, which afflicts approximately 4.7 million people in the major markets according to Clarivate epidemiology, is a heterogeneous condition requiring individualized treatment based largely on…
For neurologists, established molecules like leveteriacetam, lamotrigine, and carbamazepine remain the first choice of treatment for epilepsy; however, the new entrants in the market are evoloving…
Epilepsy is a heterogeneous condition requiring individualized treatment, and a substantial number of patients are treatment-refractory. Neurologists consider many factors when selecting an…
Epilepsy is a heterogeneous condition requiring individualized treatment, especially for patients who are persistently refractory to treatment. Neurologists consider many factors when selecting…
Epilepsy, which afflicts approximately 4.7 million people in the major pharmaceutical markets under study according to Clarivate epidemiology, is a heterogeneous condition requiring individualized…
DS is a rare, severe, pediatric-onset genetic epileptic encephalopathy characterized by developmental delay and multiple types of difficult-to-treat seizures. In particular, convulsive seizures…
Epilepsy, which afflicts approximately 4.7 million people in the major markets according to DRG epidemiology, is a heterogeneous condition requiring individualized treatment based largely on a…
More than two dozen antiepileptic drugs (AEDs) are available in the United States, yet approximately one-third of epilepsy patients are refractory to AED treatment. Opportunity in this arena has…
Despite the large number of currently marketed antiepileptic drugs (AEDs), important unmet needs remain for new therapies to treat refractory epilepsy and seizure syndromes such as Lennox-Gastaut…
Epilepsy is a heterogeneous condition requiring individualized treatment—especially for patients who are persistently refractory to treatment. Neurologists consider many factors when selecting…
Epilepsy, which afflicts approximately 4.7 million people in the G7 according to DRGepidemiology, is a heterogeneous condition requiring individualized treatment based largely on a patient’s…
DRG epidemiologists estimate that 40% of epilepsy patients experience generalized-onset seizures (GOS). The most commonly prescribed early-line treatments for GOS are older antiepileptic drugs (…